LOGIN  |  REGISTER
Cue Biopharma

List of Biotechnology Stocks

Company
Last Trade
Change
Volume
Shares Out
Market Cap
US$ 433.15
7.55 1.77
1.12M
253.72M
US$ 109.900B
US$ 742.00
-8.11 -1.08
529,031
103.28M
US$ 76.630B
US$ 464.93
10.37 2.28
826,834
132.11M
US$ 61.420B
US$ 915.36
19.99 2.23
306,505
61.57M
US$ 56.360B
US$ 206.60
-4.81 -2.28
848,401
213.27M
US$ 44.060B
US$ 96.11
-1.28 -1.31
3.30M
240.46M
US$ 23.110B
US$ 474.14
-5.81 -1.21
205,154
43.06M
US$ 20.420B
US$ 101.44
-0.60 -0.59
1.73M
196.32M
US$ 19.910B
US$ 31.71
0.32 1.02
1.08M
615.99M
US$ 19.530B
US$ 184.71
0.00 0.00
0
97.68M
US$ 18.040B
US$ 39.53
-0.37 -0.93
5.27M
427.25M
US$ 16.890B
US$ 152.48
1.60 1.06
661,270
99.71M
US$ 15.200B
US$ 75.31
-0.49 -0.65
1.07M
193.32M
US$ 14.560B
US$ 131.87
0.00 0.00
0
106.24M
US$ 14.010B
US$ 20.10
-0.12 -0.59
3.37M
695.49M
US$ 13.980B
US$ 71.46
-0.32 -0.45
1.61M
192.71M
US$ 13.770B
US$ 81.31
-0.68 -0.83
1.96M
161.97M
US$ 13.170B
US$ 573.15
-6.30 -1.09
172,757
22.71M
US$ 13.020B
US$ 17.25
-0.01 -0.06
3.95M
744.44M
US$ 12.840B
US$ 202.16
-8.69 -4.12
1.36M
61.10M
US$ 12.350B
US$ 43.44
0.01 0.02
1.63M
268.11M
US$ 11.650B
US$ 32.44
-0.13 -0.40
2,780
349.00M
US$ 11.320B
US$ 71.54
0.19 0.27
1.32M
150.68M
US$ 10.780B
US$ 53.89
-1.14 -2.07
1.49M
192.11M
US$ 10.350B
US$ 166.71
-5.41 -3.14
1.42M
60.77M
US$ 10.130B
US$ 62.95
-0.81 -1.27
970,278
155.81M
US$ 9.810B
US$ 24.06
-0.10 -0.41
8.62M
390.73M
US$ 9.400B
US$ 106.91
0.00 0.00
0
84.98M
US$ 9.090B
US$ 115.00
-4.92 -4.10
661,850
77.90M
US$ 8.960B
US$ 80.76
0.98 1.23
1.24M
105.19M
US$ 8.500B
US$ 129.46
0.00 0.00
0
64.58M
US$ 8.360B
US$ 57.95
1.70 3.02
2.06M
135.81M
US$ 7.870B
US$ 66.54
-1.56 -2.29
1.88M
117.60M
US$ 7.830B
US$ 63.51
-2.54 -3.85
1.46M
122.26M
US$ 7.760B
US$ 26.11
0.06 0.23
13.78M
282.15M
US$ 7.370B
US$ 95.99
0.05 0.05
1.17M
75.85M
US$ 7.280B
US$ 142.09
-6.94 -4.66
656,571
50.41M
US$ 7.160B
US$ 104.96
-1.46 -1.37
288,744
67.27M
US$ 7.060B
US$ 219.89
0.16 0.07
786,846
31.45M
US$ 6.920B
US$ 101.39
-3.65 -3.47
460,508
66.74M
US$ 6.770B
US$ 215.06
-0.05 -0.02
201,615
29.00M
US$ 6.240B
US$ 38.98
-0.78 -1.96
4.66M
153.51M
US$ 5.980B
US$ 44.70
-0.82 -1.80
1.30M
130.91M
US$ 5.850B
US$ 84.65
-0.99 -1.16
777,443
62.52M
US$ 5.290B
US$ 147.00
-7.02 -4.56
3.59M
34.89M
US$ 5.130B
US$ 52.22
0.05 0.10
941,262
95.30M
US$ 4.980B
US$ 26.69
-0.15 -0.56
1.72M
184.69M
US$ 4.930B
US$ 30.63
-1.04 -3.28
1.65M
158.76M
US$ 4.860B
US$ 28.97
0.07 0.24
1.62M
165.12M
US$ 4.780B
US$ 32.19
-0.26 -0.80
1.20M
145.68M
US$ 4.690B
US$ 64.27
-2.59 -3.87
518,521
71.95M
US$ 4.620B
US$ 19.25
-0.13 -0.67
2.18M
238.00M
US$ 4.580B
US$ 97.50
-0.99 -1.01
492,724
46.27M
US$ 4.510B
US$ 54.49
0.05 0.09
3.75M
82.32M
US$ 4.490B
US$ 179.12
-5.44 -2.95
832,375
25.01M
US$ 4.480B
US$ 38.33
-1.28 -3.23
594,046
113.39M
US$ 4.350B
US$ 25.43
0.58 2.33
1.48M
169.18M
US$ 4.300B
US$ 45.01
-0.24 -0.53
1.33M
94.89M
US$ 4.270B
US$ 41.08
-0.91 -2.17
2.43M
102.01M
US$ 4.190B
US$ 28.51
0.04 0.14
2.07M
146.08M
US$ 4.160B
US$ 68.81
-1.47 -2.09
809,752
57.82M
US$ 3.980B
US$ 22.02
-0.73 -3.21
695,102
175.28M
US$ 3.860B
US$ 195.10
-1.87 -0.95
120,668
19.68M
US$ 3.840B
US$ 69.13
0.17 0.25
530,957
54.83M
US$ 3.790B
US$ 46.16
-0.23 -0.50
551,067
79.05M
US$ 3.650B
US$ 29.43
-0.94 -3.10
2.34M
122.49M
US$ 3.600B
US$ 69.88
-0.13 -0.19
247,122
51.39M
US$ 3.590B
US$ 46.99
0.00 0.00
0
75.35M
US$ 3.540B
US$ 79.44
-0.53 -0.66
330,983
42.45M
US$ 3.370B
US$ 89.29
-2.40 -2.62
314,410
37.75M
US$ 3.370B
US$ 41.37
-1.88 -4.35
628,625
80.67M
US$ 3.340B
US$ 42.88
-0.63 -1.45
876,948
77.28M
US$ 3.310B
US$ 33.47
0.10 0.30
762,595
96.48M
US$ 3.230B
US$ 25.43
-0.67 -2.57
2.53M
123.73M
US$ 3.150B
US$ 39.15
-1.59 -3.90
1.14M
79.14M
US$ 3.100B
US$ 33.99
-1.20 -3.41
1.60M
89.47M
US$ 3.040B
US$ 9.73
-0.07 -0.71
4.96M
308.53M
US$ 3.000B
US$ 33.69
-0.62 -1.81
286,183
87.67M
US$ 2.950B
US$ 30.43
-1.02 -3.24
891,090
95.37M
US$ 2.900B
US$ 18.69
-0.15 -0.80
1.08M
152.67M
US$ 2.850B
US$ 19.99
-0.62 -3.01
3.34M
142.82M
US$ 2.850B
US$ 22.62
-0.07 -0.31
797,252
122.91M
US$ 2.780B
US$ 30.80
-1.25 -3.90
1.36M
87.00M
US$ 2.680B
US$ 17.84
-0.32 -1.76
840,039
146.66M
US$ 2.620B
US$ 20.66
-0.54 -2.55
1.27M
126.53M
US$ 2.610B
US$ 48.12
-0.91 -1.86
1.33M
53.71M
US$ 2.580B
US$ 7.47
-0.41 -5.20
4.69M
341.83M
US$ 2.550B
US$ 22.98
-2.29 -9.06
1.01M
105.87M
US$ 2.430B
US$ 11.25
-0.46 -3.93
2.68M
213.05M
US$ 2.400B
US$ 37.25
4.25 12.88
5.42M
63.93M
US$ 2.380B
US$ 23.37
-0.68 -2.83
1.60M
101.47M
US$ 2.370B
US$ 14.89
0.00 0.00
0
148.49M
US$ 2.210B
US$ 28.40
-0.26 -0.91
591,910
77.59M
US$ 2.200B
US$ 27.15
-0.80 -2.86
3.84M
80.16M
US$ 2.180B
US$ 19.52
-0.35 -1.76
1.01M
110.59M
US$ 2.160B
US$ 20.47
0.75 3.80
3.50M
104.79M
US$ 2.150B
US$ 16.57
-0.43 -2.53
195,884
128.29M
US$ 2.130B
US$ 15.91
-0.26 -1.61
1.18M
131.84M
US$ 2.100B
US$ 31.35
0.22 0.71
63,155
65.90M
US$ 2.070B
US$ 36.01
0.50 1.41
322,903
57.60M
US$ 2.070B
US$ 59.98
0.00 0.00
0
34.44M
US$ 2.070B
US$ 2.08
-0.22 -9.57
26.51M
984.97M
US$ 2.050B
US$ 22.85
0.42 1.87
598,481
85.15M
US$ 1.950B
US$ 32.12
-2.45 -7.09
1.28M
60.68M
US$ 1.950B
US$ 37.65
-1.17 -3.01
383,391
50.57M
US$ 1.900B
US$ 25.10
-0.93 -3.57
768,763
74.84M
US$ 1.880B
US$ 36.17
-1.42 -3.78
117,249
50.53M
US$ 1.830B
US$ 42.28
-0.92 -2.13
469,679
42.88M
US$ 1.810B
US$ 26.67
0.75 2.89
578,170
66.45M
US$ 1.770B
US$ 5.59
0.16 2.95
6.35M
307.07M
US$ 1.720B
US$ 13.35
0.05 0.38
3.81M
128.23M
US$ 1.710B
US$ 29.81
-0.28 -0.93
462,660
57.12M
US$ 1.700B
US$ 16.35
-0.56 -3.31
1.38M
101.37M
US$ 1.660B
US$ 18.79
-0.33 -1.73
1.30M
86.91M
US$ 1.630B
US$ 27.29
-0.55 -1.98
1.04M
58.31M
US$ 1.590B
US$ 25.32
-1.25 -4.70
2.05M
62.29M
US$ 1.580B
US$ 17.09
-1.23 -6.71
934,384
91.71M
US$ 1.570B
US$ 20.98
-0.18 -0.85
820,439
74.77M
US$ 1.570B
US$ 24.12
-1.87 -7.20
220,962
64.96M
US$ 1.570B
US$ 13.75
-0.49 -3.44
619,781
109.82M
US$ 1.510B
US$ 7.16
0.03 0.42
6.63M
210.54M
US$ 1.510B
US$ 33.16
0.16 0.48
627,685
44.90M
US$ 1.490B
US$ 4.60
-0.24 -4.96
410,824
311.60M
US$ 1.430B
US$ 3.87
0.03 0.78
14.90M
363.19M
US$ 1.410B
US$ 10.08
-0.34 -3.26
1.67M
134.68M
US$ 1.360B
US$ 5.54
-0.05 -0.89
2.66M
242.97M
US$ 1.350B
US$ 25.01
-3.97 -13.70
1.14M
54.04M
US$ 1.350B
US$ 7.49
0.09 1.22
1.68M
173.32M
US$ 1.300B
US$ 27.12
-1.43 -5.01
327,006
47.66M
US$ 1.290B
US$ 10.88
0.17 1.59
2.14M
117.42M
US$ 1.280B
US$ 3.48
-0.13 -3.60
2.71M
353.82M
US$ 1.230B
US$ 47.98
0.00 0.00
0
25.69M
US$ 1.230B
US$ 20.56
0.71 3.58
480,213
59.35M
US$ 1.220B
US$ 9.89
-0.37 -3.61
325,160
121.56M
US$ 1.200B
US$ 82.25
1.48 1.83
65,199
14.54M
US$ 1.200B
US$ 9.00
-0.32 -3.43
2.60M
132.69M
US$ 1.190B
US$ 5.81
-0.03 -0.51
4.16M
203.47M
US$ 1.180B
US$ 12.75
0.31 2.49
554,892
92.40M
US$ 1.180B
US$ 22.00
0.06 0.27
687,398
53.05M
US$ 1.170B
US$ 12.06
-0.20 -1.63
1.38M
97.22M
US$ 1.170B
US$ 6.99
-0.42 -5.67
1.77M
167.18M
US$ 1.170B
US$ 26.17
-1.45 -5.25
181,719
44.77M
US$ 1.170B
US$ 5.11
-0.09 -1.73
1.95M
225.17M
US$ 1.150B
US$ 24.38
-4.08 -14.34
1.64M
46.81M
US$ 1.140B
US$ 15.99
-0.52 -3.15
453,504
71.41M
US$ 1.140B
US$ 40.90
-0.41 -0.99
390,938
27.69M
US$ 1.130B
US$ 13.69
-0.57 -4.00
573,588
82.79M
US$ 1.130B
US$ 54.85
-6.26 -10.24
794,104
20.34M
US$ 1.120B
US$ 20.92
0.11 0.53
282,473
53.37M
US$ 1.120B
US$ 16.21
-0.02 -0.12
14,230
68.51M
US$ 1.110B
US$ 4.06
-0.37 -8.35
5.07M
273.92M
US$ 1.110B
US$ 18.79
-0.21 -1.11
109,354
57.81M
US$ 1.090B
US$ 40.00
0.00 0.00
0
27.02M
US$ 1.080B
US$ 6.60
-0.09 -1.35
2.52M
162.50M
US$ 1.070B
US$ 6.47
-0.49 -7.04
7.86M
165.92M
US$ 1.070B
US$ 3.97
-0.03 -0.75
10.15M
266.37M
US$ 1.060B
US$ 14.74
-0.20 -1.34
783,159
71.14M
US$ 1.050B
US$ 3.46
-0.01 -0.29
2.69M
299.34M
US$ 1.040B
US$ 10.65
-0.50 -4.48
1.50M
97.39M
US$ 1.040B
US$ 15.41
-0.37 -2.34
416,081
65.12M
US$ 1.000B
US$ 15.55
0.00 0.00
0
64.53M
US$ 1.000B
US$ 11.13
0.00 0.00
0
89.31M
US$ 994.020M
US$ 20.49
0.00 0.00
18,877
48.22M
US$ 988.030M
US$ 11.27
-0.17 -1.49
1.07M
87.02M
US$ 980.720M
US$ 15.93
-18.06 -53.13
33.23M
60.15M
US$ 958.190M
US$ 8.11
-0.31 -3.68
5.87M
115.83M
US$ 939.610M
US$ 17.15
-0.18 -1.04
351,809
54.78M
US$ 939.480M
US$ 18.43
-1.18 -6.02
338,287
50.67M
US$ 933.850M
US$ 9.50
0.00 0.00
0
97.47M
US$ 925.960M
US$ 10.10
0.42 4.34
1.54M
88.80M
US$ 896.880M
US$ 32.33
0.82 2.60
882,268
27.71M
US$ 895.860M
US$ 9.04
-0.36 -3.83
2.30M
98.85M
US$ 893.600M
US$ 12.52
-0.73 -5.51
1.15M
70.85M
US$ 887.040M
US$ 14.05
-0.16 -1.13
171,870
62.03M
US$ 871.520M
US$ 3.66
-0.06 -1.61
8.70M
237.07M
US$ 867.680M
US$ 8.43
-0.35 -3.99
1.25M
102.68M
US$ 865.590M
US$ 20.75
-1.77 -7.86
260,622
41.28M
US$ 856.560M
US$ 2.15
-0.08 -3.59
25.23M
396.97M
US$ 853.490M
US$ 27.19
-3.21 -10.56
918,143
31.29M
US$ 850.780M
US$ 4.35
0.00 0.00
207,570
191.02M
US$ 830.940M
US$ 8.89
-0.28 -3.05
1.46M
92.73M
US$ 824.370M
US$ 2.89
-0.11 -3.67
2.05M
283.71M
US$ 819.920M
US$ 44.41
-2.85 -6.03
776,010
18.15M
US$ 806.040M
US$ 4.17
-0.04 -0.95
698,294
192.32M
US$ 801.970M
US$ 12.49
0.00 0.00
0
63.96M
US$ 798.860M
US$ 1.23
0.04 3.36
19.75M
638.36M
US$ 785.180M
US$ 10.00
0.29 2.99
6.85M
78.44M
US$ 784.400M
US$ 5.63
-0.44 -7.25
4.02M
139.13M
US$ 783.300M
US$ 9.78
-0.01 -0.10
1.71M
78.79M
US$ 770.570M
US$ 8.77
-0.13 -1.46
26,408
85.92M
US$ 753.520M
US$ 11.66
-0.15 -1.27
777,866
64.22M
US$ 748.810M
US$ 9.78
-0.56 -5.42
2.05M
75.32M
US$ 736.630M
US$ 7.58
-0.09 -1.17
20,644
96.33M
US$ 730.180M
US$ 5.93
-0.27 -4.35
2.09M
122.00M
US$ 723.460M
US$ 7.41
0.06 0.82
1.28M
97.21M
US$ 720.330M
US$ 17.16
0.00 0.00
0
41.89M
US$ 718.830M
US$ 2.99
-0.15 -4.78
7.08M
231.46M
US$ 692.070M
US$ 13.52
-0.40 -2.87
567,101
50.55M
US$ 683.440M
US$ 9.43
-0.25 -2.58
1.40M
70.90M
US$ 668.590M
US$ 3.81
-0.48 -11.19
5.92M
169.44M
US$ 645.570M
US$ 7.75
-0.09 -1.15
498,265
80.49M
US$ 623.800M
US$ 12.21
-0.39 -3.10
457,080
50.62M
US$ 618.070M
US$ 8.32
-0.60 -6.73
1.31M
72.99M
US$ 607.280M
US$ 4.06
-0.07 -1.69
4.28M
149.06M
US$ 605.180M
US$ 10.20
-0.55 -5.12
1.41M
59.08M
US$ 602.620M
US$ 8.05
-0.46 -5.41
1.81M
74.68M
US$ 601.170M
US$ 7.83
0.00 0.00
0
76.38M
US$ 598.060M
US$ 3.30
-0.20 -5.71
8.61M
180.51M
US$ 595.680M
US$ 8.21
-1.17 -12.47
6.22M
71.36M
US$ 585.790M
US$ 3.41
0.00 0.00
0
171.00M
US$ 583.110M
US$ 10.13
-0.38 -3.62
1.47M
57.14M
US$ 578.830M
US$ 4.60
0.36 8.49
1.27M
123.88M
US$ 569.850M
US$ 8.16
0.00 0.00
0
69.23M
US$ 564.920M
US$ 10.35
0.08 0.78
423,692
53.83M
US$ 557.140M
US$ 8.68
0.00 0.00
0
62.78M
US$ 544.930M
US$ 33.99
0.13 0.38
51,799
15.82M
US$ 537.720M
US$ 4.64
0.00 0.00
0
115.27M
US$ 534.850M
US$ 16.83
-0.35 -2.04
434,109
30.47M
US$ 512.810M
US$ 8.94
-0.01 -0.11
422,298
56.96M
US$ 509.220M
US$ 75.94
-7.12 -8.57
200,725
6.68M
US$ 507.280M
US$ 2.16
-0.34 -13.60
9.18M
233.12M
US$ 503.540M
US$ 12.90
-0.08 -0.62
2.50M
38.87M
US$ 501.420M
US$ 3.44
0.06 1.78
571,561
145.02M
US$ 498.870M
US$ 70.34
0.12 0.17
365,978
7.09M
US$ 498.710M
US$ 4.76
-0.17 -3.45
3.58M
104.34M
US$ 496.660M
US$ 1.34
-0.02 -1.47
2.47M
363.40M
US$ 486.960M
US$ 8.95
-0.92 -9.32
1.12M
54.12M
US$ 484.370M
C$ 5.95
0.15 2.59
112,719
78.34M
C$ 466.120M
US$ 8.17
-0.17 -2.04
1.50M
56.30M
US$ 459.970M
US$ 3.03
-0.01 -0.33
4.42M
150.37M
US$ 455.620M
US$ 10.15
0.00 0.00
0
44.21M
US$ 448.730M
US$ 20.81
-1.29 -5.84
38,001
21.22M
US$ 441.590M
US$ 6.69
-0.40 -5.64
591,543
64.57M
US$ 431.970M
US$ 5.93
-0.25 -4.05
225,236
71.61M
US$ 424.650M
C$ 8.27
-0.12 -1.43
116,654
50.65M
C$ 418.880M
US$ 8.59
-0.06 -0.69
646,890
48.52M
US$ 416.790M
US$ 7.98
-0.21 -2.56
944,569
52.08M
US$ 415.600M
US$ 15.37
-0.08 -0.52
159,397
26.82M
US$ 412.220M
US$ 16.79
0.23 1.39
390
24.17M
US$ 405.810M
US$ 13.96
-0.18 -1.27
182,948
28.85M
US$ 402.750M
US$ 5.10
-0.11 -2.11
2.13M
77.91M
US$ 397.340M
US$ 11.65
-0.58 -4.74
173,658
33.86M
US$ 394.470M
US$ 8.60
0.00 0.00
0
45.44M
US$ 390.780M
US$ 1.47
-0.04 -2.65
4.54M
265.37M
US$ 390.090M
US$ 6.02
-0.19 -3.06
126,429
63.50M
US$ 382.270M
US$ 3.65
0.00 0.00
0
104.39M
US$ 381.020M
US$ 2.23
-0.19 -7.85
2.74M
169.94M
US$ 378.970M
US$ 7.15
0.00 0.00
0
52.76M
US$ 377.230M
US$ 9.85
-0.06 -0.61
258,998
38.22M
US$ 376.470M
US$ 8.05
0.00 0.00
0
46.67M
US$ 375.690M
US$ 1.61
-0.05 -3.01
1.96M
230.33M
US$ 370.830M
US$ 29.76
-1.32 -4.25
72,474
12.38M
US$ 368.430M
US$ 4.26
0.00 0.00
0
86.32M
US$ 367.720M
US$ 1.16
-0.02 -1.69
16.26M
312.32M
US$ 362.290M
US$ 1.87
0.07 3.89
906,323
192.09M
US$ 359.210M
US$ 1.34
-0.04 -2.90
1.59M
266.14M
US$ 356.630M
US$ 0.23
-0.02 -6.12
3.11M
1.54B
US$ 354.200M
US$ 5.46
-0.05 -0.91
287,157
64.47M
US$ 352.010M
US$ 5.07
-0.72 -12.44
1.87M
68.75M
US$ 348.630M
US$ 12.80
-0.28 -2.14
177,749
26.97M
US$ 345.220M
US$ 6.87
-0.17 -2.41
712,953
49.93M
US$ 343.020M
US$ 4.71
0.04 0.86
133,714
72.33M
US$ 340.670M
US$ 6.63
0.00 0.00
105,099
50.91M
US$ 337.530M
US$ 3.09
-0.07 -2.22
1.13M
108.22M
US$ 334.400M
US$ 3.74
-0.08 -2.09
1.89M
89.35M
US$ 334.170M
US$ 3.87
0.09 2.38
45,101
85.26M
US$ 329.960M
US$ 15.53
-0.06 -0.38
52,805
20.79M
US$ 322.870M
US$ 2.25
-0.01 -0.44
4.20M
141.55M
US$ 318.490M
US$ 8.49
-0.44 -4.93
137,580
35.86M
US$ 304.450M
US$ 5.67
0.00 0.00
0
53.68M
US$ 304.370M
US$ 1.34
-0.03 -2.19
2.55M
224.73M
US$ 301.140M
US$ 19.24
-1.24 -6.05
176,699
15.49M
US$ 298.030M
US$ 4.04
-0.38 -8.60
8.65M
73.33M
US$ 296.250M
US$ 4.87
-0.37 -7.06
1.47M
60.16M
US$ 292.980M
US$ 2.70
0.09 3.45
1.19M
108.35M
US$ 292.540M
US$ 6.36
-0.29 -4.36
3.45M
45.72M
US$ 290.780M
US$ 4.92
-0.10 -1.99
356,685
59.10M
US$ 290.770M
US$ 15.87
-0.91 -5.42
335,478
18.13M
US$ 287.720M
US$ 6.56
-0.17 -2.53
425,764
43.80M
US$ 287.330M
US$ 3.20
0.05 1.43
1.45M
87.44M
US$ 279.370M
US$ 2.77
0.03 1.09
922,254
100.60M
US$ 278.660M
US$ 1.75
-0.09 -4.89
4.62M
159.13M
US$ 278.480M
US$ 5.51
-0.49 -8.17
985,604
49.89M
US$ 274.890M
US$ 1.83
-0.04 -2.14
12.13M
149.00M
US$ 272.670M
US$ 1.84
-0.14 -7.07
157,283
147.19M
US$ 270.830M
US$ 4.77
-0.22 -4.41
94,818
56.46M
US$ 269.310M
US$ 3.12
-0.43 -12.11
2.95M
85.59M
US$ 267.040M
US$ 5.00
0.00 0.00
0
53.23M
US$ 266.150M
US$ 7.61
-0.12 -1.55
205,060
34.15M
US$ 259.880M
US$ 4.00
0.00 0.00
0
64.56M
US$ 258.240M
US$ 1.98
0.00 0.00
191,960
126.31M
US$ 250.090M
US$ 4.55
-0.23 -4.81
1.22M
54.19M
US$ 246.560M
US$ 1.71
-0.03 -1.72
204,188
143.96M
US$ 246.170M
US$ 4.87
-0.09 -1.81
205,432
50.39M
US$ 245.400M
US$ 1.79
0.23 14.74
17.62M
137.04M
US$ 245.300M
US$ 3.91
-0.48 -10.93
2.20M
62.26M
US$ 243.440M
US$ 4.42
-0.06 -1.34
573,857
54.90M
US$ 242.660M
US$ 4.29
-0.11 -2.50
77,004
56.55M
US$ 242.600M
US$ 4.85
0.00 0.00
0
50.00M
US$ 242.500M
US$ 10.49
-0.50 -4.55
105,464
23.10M
US$ 242.320M
US$ 4.54
-0.11 -2.37
639,974
53.23M
US$ 241.660M
US$ 6.22
-0.52 -7.72
1.24M
38.59M
US$ 240.030M
US$ 19.09
0.89 4.89
40,267
12.53M
US$ 239.200M
US$ 1.26
-0.02 -1.56
9.15M
187.27M
US$ 235.960M
US$ 3.00
-0.09 -2.91
514,015
78.13M
US$ 234.390M
US$ 2.27
0.00 0.00
0
100.95M
US$ 229.160M
US$ 3.51
-0.21 -5.65
312,804
65.02M
US$ 228.220M
US$ 2.65
-0.04 -1.49
5.11M
85.17M
US$ 225.700M
US$ 0.95
0.04 3.81
4.03M
236.29M
US$ 225.420M
US$ 2.34
-0.09 -3.70
8.12M
96.27M
US$ 225.270M
US$ 17.35
0.14 0.81
130,842
12.82M
US$ 222.430M
US$ 4.47
0.00 0.00
0
48.36M
US$ 216.170M
US$ 1.17
0.02 1.83
3.83M
183.36M
US$ 214.710M
US$ 1.79
0.00 0.00
1.95M
118.82M
US$ 212.690M
US$ 3.77
-0.18 -4.56
599,002
55.60M
US$ 209.610M
US$ 2.11
-0.08 -3.65
4.68M
97.62M
US$ 205.980M
US$ 1.95
-0.17 -8.02
928,889
105.35M
US$ 205.430M
US$ 1.22
-0.06 -4.69
1.92M
166.51M
US$ 203.140M
US$ 1.41
-0.09 -6.00
23.64M
142.44M
US$ 200.840M
US$ 3.48
-0.29 -7.69
1.10M
56.97M
US$ 198.260M
US$ 5.31
-1.46 -21.57
184,464
36.33M
US$ 192.910M
US$ 3.38
0.21 6.62
2.68M
55.68M
US$ 188.200M
US$ 6.02
-0.78 -11.47
1.22M
31.00M
US$ 186.620M
C$ 2.40
0.06 2.56
1,200
76.38M
C$ 183.310M
US$ 15.52
0.30 1.97
511,888
11.78M
US$ 182.830M
US$ 10.28
-0.47 -4.37
217,606
17.55M
US$ 180.410M
US$ 4.73
-0.16 -3.27
302,441
38.05M
US$ 179.980M
US$ 1.95
0.05 2.63
14,088
92.18M
US$ 179.750M
US$ 6.25
-0.24 -3.70
499,653
28.41M
US$ 177.560M
US$ 6.71
-0.59 -8.08
406,831
26.00M
US$ 174.460M
US$ 1.41
-0.09 -6.00
835,419
121.27M
US$ 170.990M
US$ 7.33
0.16 2.23
29,956
23.24M
US$ 170.350M
US$ 7.53
-0.15 -1.95
995,082
21.91M
US$ 164.980M
US$ 1.76
-0.01 -0.56
2.19M
93.47M
US$ 164.510M
US$ 4.32
0.30 7.46
1,491
37.40M
US$ 161.570M
US$ 2.48
0.07 2.90
526,391
63.28M
US$ 156.930M
US$ 16.70
-0.64 -3.69
91,085
9.05M
US$ 151.140M
US$ 0.44
0.02 4.37
302.12M
336.49M
US$ 149.400M
US$ 1.65
0.00 0.00
1.97M
90.32M
US$ 149.030M
US$ 5.81
-0.13 -2.19
62,206
25.61M
US$ 148.790M
US$ 2.66
-0.11 -3.97
1.11M
55.90M
US$ 148.690M
US$ 21.99
0.00 0.00
0
6.60M
US$ 145.130M
US$ 3.66
-0.77 -17.38
2.88M
39.50M
US$ 144.570M
US$ 1.61
0.00 0.00
677,640
88.27M
US$ 142.110M
US$ 4.17
-0.15 -3.47
425,805
34.01M
US$ 141.820M
US$ 1.17
-0.10 -7.87
1.46M
120.87M
US$ 141.420M
US$ 1.51
0.01 0.67
206,803
93.54M
US$ 141.250M
US$ 2.89
-0.14 -4.62
1.17M
48.31M
US$ 139.620M
US$ 4.20
-0.20 -4.55
94,351
32.92M
US$ 138.260M
US$ 27.52
0.09 0.33
21,963
5.00M
US$ 137.600M
US$ 2.04
-0.13 -5.99
3.07M
67.36M
US$ 137.410M
US$ 9.43
-0.33 -3.38
171,632
14.42M
US$ 135.980M
US$ 1.39
-0.09 -6.08
3.42M
97.54M
US$ 135.580M
US$ 1.67
-0.03 -1.76
635,487
80.42M
US$ 134.300M
US$ 15.54
-0.58 -3.60
129,526
8.57M
US$ 133.180M
US$ 1.92
0.00 0.00
5.44M
68.70M
US$ 131.900M
US$ 7.54
-1.46 -16.22
352,103
17.26M
US$ 130.140M
US$ 1.02
-0.07 -6.42
64,777
126.01M
US$ 128.530M
C$ 1.52
-0.08 -5.00
146,074
83.41M
C$ 126.780M
C$ 0.68
-0.02 -2.86
11,680
185.51M
C$ 126.150M
US$ 5.86
-0.14 -2.33
412,386
21.49M
US$ 125.930M
US$ 5.98
-0.26 -4.17
150,808
20.92M
US$ 125.100M
US$ 1.14
-0.09 -7.32
7.77M
109.15M
US$ 124.430M
US$ 5.72
0.07 1.24
117,363
21.74M
US$ 124.350M
US$ 2.20
-0.07 -3.08
1.51M
56.34M
US$ 123.950M
US$ 1.74
-0.07 -3.87
1.26M
71.03M
US$ 123.590M
US$ 1.02
-0.01 -0.97
1.59M
115.35M
US$ 117.660M
US$ 4.41
-0.10 -2.22
1.60M
26.50M
US$ 116.860M
US$ 4.79
-0.16 -3.23
227,651
24.07M
US$ 115.300M
US$ 3.12
-0.12 -3.70
1.78M
36.24M
US$ 113.070M
US$ 1.56
-0.24 -13.33
1.50M
71.21M
US$ 111.090M
US$ 1.48
-0.05 -3.27
3.94M
75.03M
US$ 111.040M
US$ 8.00
-0.24 -2.91
56,921
13.85M
US$ 110.800M
US$ 2.75
0.00 0.00
202,799
39.80M
US$ 109.450M
US$ 2.26
0.00 0.00
0
48.08M
US$ 108.660M
US$ 1.75
-0.15 -7.89
117,168
60.57M
US$ 106.000M
US$ 2.09
0.00 0.00
0
50.13M
US$ 104.770M
US$ 37.55
-1.12 -2.90
5,096
2.79M
US$ 104.760M
US$ 1.71
0.00 0.00
0
60.18M
US$ 102.910M
US$ 2.22
-0.07 -3.06
77,131
45.86M
US$ 101.810M
US$ 25.24
1.74 7.40
5,022
3.94M
US$ 99.450M
US$ 1.89
-0.01 -0.53
141,431
51.76M
US$ 97.830M
US$ 2.38
0.02 0.85
365
41.08M
US$ 97.770M
US$ 1.06
-0.01 -0.93
757,255
91.88M
US$ 97.390M
US$ 1.34
-0.02 -1.47
3.55M
72.25M
US$ 96.820M
US$ 9.26
-0.30 -3.14
124,674
10.33M
US$ 95.660M
US$ 89.20
6.09 7.33
108,550
1.07M
US$ 95.440M
US$ 1.99
0.11 5.85
36,670
47.13M
US$ 93.790M
US$ 0.88
-0.06 -6.38
7.31M
106.15M
US$ 93.410M
US$ 4.16
-0.04 -0.95
4.24M
22.08M
US$ 91.850M
US$ 1.49
-0.04 -2.61
1.90M
61.45M
US$ 91.560M
US$ 5.36
-0.39 -6.78
100,079
17.05M
US$ 91.390M
US$ 2.13
-0.005 -0.23
709,525
42.99M
US$ 91.350M
US$ 0.38
-0.0004 -0.11
144,253
240.06M
US$ 90.980M
US$ 0.70
-0.04 -5.66
9.27M
129.17M
US$ 90.420M
US$ 1.42
-0.04 -2.74
1.16M
63.26M
US$ 89.830M
US$ 1.93
0.00 0.00
0
46.15M
US$ 89.070M
US$ 12.22
-1.32 -9.75
37,413
7.21M
US$ 88.110M
US$ 0.56
-0.05 -8.24
7.10M
153.26M
US$ 85.830M
C$ 1.28
0.20 18.52
64,725
66.93M
C$ 85.670M
US$ 6.06
0.06 1.00
16,197
13.79M
US$ 83.510M
US$ 2.37
0.01 0.42
231,653
35.04M
US$ 83.040M
US$ 1.83
-0.03 -1.61
4.00M
44.42M
US$ 81.290M
US$ 0.59
0.0071 1.22
22.74M
137.43M
US$ 81.080M
US$ 1.97
-0.04 -1.99
9,755
41.12M
US$ 81.010M
US$ 3.30
-0.17 -4.90
26,910
24.54M
US$ 80.980M
US$ 2.57
-0.15 -5.51
248,932
31.04M
US$ 79.770M
US$ 0.65
-0.03 -3.98
7.60M
120.28M
US$ 78.420M
US$ 2.68
0.00 0.00
0
28.91M
US$ 77.480M
US$ 8.22
-1.00 -10.85
159,098
9.25M
US$ 76.040M
US$ 3.00
0.00 0.00
0
24.68M
US$ 74.040M
US$ 10.78
-0.66 -5.77
111,405
6.78M
US$ 73.090M
US$ 1.47
0.06 4.26
48,431
49.05M
US$ 72.100M
US$ 2.32
-0.09 -3.73
62,098
30.49M
US$ 70.740M
US$ 2.20
-0.22 -9.09
1.01M
31.56M
US$ 69.430M
US$ 0.71
-0.04 -4.87
2.00M
97.99M
US$ 69.080M
US$ 0.96
-0.05 -5.25
4.22M
70.70M
US$ 67.660M
US$ 0.99
-0.17 -14.31
1.37M
67.75M
US$ 67.340M
US$ 1.35
-0.21 -13.23
1.76M
50.02M
US$ 67.280M
US$ 5.69
0.00 0.00
0
11.82M
US$ 67.260M
US$ 3.31
0.07 2.16
34,441
20.16M
US$ 66.730M
US$ 4.60
0.31 7.23
49,212
14.41M
US$ 66.290M
US$ 1.23
-0.06 -4.65
1.66M
53.21M
US$ 65.450M
US$ 1.20
-0.12 -9.09
159,609
54.22M
US$ 65.060M
US$ 6.85
-0.70 -9.27
253,630
9.49M
US$ 65.010M
US$ 0.56
-0.05 -8.71
9.91M
115.06M
US$ 64.780M
US$ 2.27
-0.12 -5.02
3.97M
28.10M
US$ 63.790M
C$ 0.70
0.00 0.00
9,000
90.68M
C$ 63.480M
US$ 2.60
-0.01 -0.38
30,221
24.30M
US$ 63.180M
US$ 0.74
-0.06 -7.55
1.47M
85.14M
US$ 63.090M
US$ 3.78
-0.07 -1.82
49,382
16.63M
US$ 62.860M
US$ 3.34
0.07 2.14
20,512
18.13M
US$ 60.550M
US$ 1.58
-0.22 -12.22
184,061
37.77M
US$ 59.680M
US$ 1.66
-0.05 -2.92
187,905
35.21M
US$ 58.450M
US$ 1.56
-0.05 -2.81
2.82M
37.55M
US$ 58.390M
US$ 2.02
0.01 0.50
70,678
28.32M
US$ 57.210M
US$ 9.01
-0.06 -0.66
305,846
6.24M
US$ 56.220M
US$ 4.62
-0.32 -6.48
16,011
12.02M
US$ 55.530M
US$ 6.93
0.00 0.00
49,476
7.99M
US$ 55.370M
C$ 0.49
-0.02 -3.92
3,100
113.01M
C$ 55.370M
US$ 2.10
0.04 1.94
101,373
26.29M
US$ 55.210M
US$ 0.88
0.00 0.00
0
60.97M
US$ 53.650M
C$ 0.08
0.00 0.00
0
701.73M
C$ 52.630M
C$ 1.91
-0.01 -0.52
11,000
27.42M
C$ 52.370M
US$ 0.86
-0.001 -0.12
1.42M
60.89M
US$ 52.300M
US$ 10.72
-0.37 -3.34
7,318
4.69M
US$ 50.280M
US$ 0.95
-0.07 -6.67
1.38M
52.47M
US$ 49.950M
US$ 5.28
-0.12 -2.22
828,239
9.42M
US$ 49.740M
US$ 9.21
-0.09 -0.97
158,734
5.35M
US$ 49.270M
US$ 9.81
0.00 0.00
0
5.02M
US$ 49.250M
US$ 4.97
0.00 0.00
0
9.79M
US$ 48.660M
US$ 1.14
0.00 0.00
0
41.10M
US$ 46.850M
US$ 0.80
0.0032 0.40
6.02M
58.79M
US$ 46.740M
US$ 1.27
0.00 0.00
0
36.59M
US$ 46.470M
US$ 0.53
-0.01 -2.08
1.67M
87.31M
US$ 46.360M
US$ 5.10
0.36 7.59
11,022
9.05M
US$ 46.160M
C$ 0.14
-0.02 -12.50
87,700
328.69M
C$ 46.020M
US$ 2.73
0.00 0.00
0
16.84M
US$ 45.970M
US$ 1.74
0.00 0.00
0
26.31M
US$ 45.780M
US$ 0.63
-0.05 -7.33
2.32M
71.95M
US$ 45.470M
US$ 1.45
-0.02 -1.36
3,119
31.24M
US$ 45.300M
US$ 1.93
-0.09 -4.46
42,623
23.43M
US$ 45.220M
US$ 6.15
-0.07 -1.13
20,621
7.32M
US$ 45.020M
C$ 0.82
0.02 2.50
48,100
54.73M
C$ 44.880M
US$ 3.14
-0.03 -0.95
36,906
14.13M
US$ 44.370M
US$ 1.29
0.00 0.00
140,875
34.38M
US$ 44.350M
US$ 1.18
-0.02 -1.67
685,819
37.03M
US$ 43.700M
US$ 1.56
-0.16 -9.30
409.86M
27.98M
US$ 43.650M
US$ 1.38
0.01 0.73
112,575
31.20M
US$ 43.060M
US$ 5.12
-0.32 -5.88
94,699
8.34M
US$ 42.700M
US$ 0.10
0.0079 8.77
1,030
434.93M
US$ 42.620M
US$ 12.55
-0.86 -6.41
29,174
3.39M
US$ 42.540M
US$ 1.57
0.00 0.00
1.18M
26.59M
US$ 41.750M
US$ 0.86
-0.06 -6.20
4.37M
48.54M
US$ 41.740M
US$ 3.90
0.00 0.00
5,740
10.66M
US$ 41.570M
US$ 0.75
0.04 5.06
2.31M
54.72M
US$ 41.260M
US$ 1.87
-0.19 -9.22
367,161
21.87M
US$ 40.900M
C$ 0.14
0.02 16.67
120,681
287.34M
C$ 40.230M
US$ 3.10
0.00 0.00
0
12.59M
US$ 39.030M
US$ 1.48
-0.02 -1.33
207,084
26.29M
US$ 38.910M
US$ 3.47
-0.04 -1.14
32,880
11.18M
US$ 38.790M
US$ 10.18
-1.32 -11.48
1,300
3.81M
US$ 38.790M
US$ 4.34
0.00 0.00
0
8.65M
US$ 37.540M
US$ 0.71
-0.03 -4.39
452,670
52.50M
US$ 37.120M
US$ 9.70
1.13 13.19
134,988
3.82M
US$ 37.050M
C$ 0.22
-0.03 -12.00
1,000
165.94M
C$ 36.510M
US$ 1.13
-0.08 -6.61
785,509
32.06M
US$ 36.230M
US$ 5.54
0.16 2.97
54,999
6.37M
US$ 35.290M
US$ 2.03
0.00 0.00
641,927
17.34M
US$ 35.200M
US$ 1.33
0.00 0.00
0
26.20M
US$ 34.850M
US$ 5.05
-0.01 -0.20
39,627
6.74M
US$ 34.040M
US$ 1.14
-0.02 -1.72
160,229
29.70M
US$ 33.860M
C$ 0.65
0.02 3.17
10,500
51.84M
C$ 33.700M
US$ 2.62
-0.22 -7.75
43,282
12.86M
US$ 33.690M
C$ 0.24
0.00 0.00
28,873
140.26M
C$ 33.660M
US$ 1.42
0.00 0.00
0
23.18M
US$ 32.920M
US$ 0.91
-0.03 -2.69
355,087
36.19M
US$ 32.750M
US$ 8.08
-0.45 -5.28
35,745
4.05M
US$ 32.720M
C$ 0.43
0.00 0.00
0
74.76M
C$ 32.150M
US$ 0.22
-0.02 -8.79
30.86M
144.30M
US$ 31.750M
US$ 3.36
-0.01 -0.30
4,447
9.25M
US$ 31.080M
US$ 0.85
-0.01 -1.39
643,210
36.65M
US$ 30.970M
US$ 19.34
1.57 8.84
221,591
1.59M
US$ 30.750M
US$ 0.55
0.00 0.00
0
55.22M
US$ 30.370M
US$ 13.90
-1.10 -7.33
7,637
2.14M
US$ 29.750M
US$ 0.33
0.00 0.00
0
90.38M
US$ 29.740M
US$ 0.72
-0.07 -8.42
80,197
40.83M
US$ 29.230M
US$ 0.30
-0.01 -4.13
234,227
92.87M
US$ 28.050M
US$ 0.65
0.0022 0.34
90,885
42.24M
US$ 27.460M
US$ 2.14
0.07 3.38
17,225
12.78M
US$ 27.350M
US$ 3.89
0.27 7.46
186,277
6.76M
US$ 26.300M
US$ 0.63
0.00 0.00
0
41.21M
US$ 25.840M
US$ 8.03
-0.19 -2.31
21,856
3.18M
US$ 25.540M
US$ 1.09
0.00 0.00
147,880
22.39M
US$ 24.410M
US$ 5.32
0.00 0.00
0
4.57M
US$ 24.310M
US$ 1.08
-0.02 -1.82
924,953
22.49M
US$ 24.290M
US$ 1.06
0.00 0.00
77,659
22.23M
US$ 23.560M
US$ 4.37
-0.02 -0.46
22,925
5.38M
US$ 23.510M
US$ 1.26
-0.09 -6.67
350,531
18.47M
US$ 23.270M
US$ 1.72
0.05 2.99
99,392
13.48M
US$ 23.190M
US$ 3.25
-0.55 -14.47
66,583
6.99M
US$ 22.720M
US$ 0.37
0.00 0.00
0
59.25M
US$ 21.630M
US$ 1.27
-0.05 -3.79
472,527
16.85M
US$ 21.400M
US$ 0.36
-0.02 -6.37
7.35M
60.06M
US$ 21.380M
C$ 0.16
0.00 0.00
0
132.87M
C$ 21.260M
US$ 2.05
-0.01 -0.49
34,249
10.19M
US$ 20.890M
US$ 1.74
-0.07 -3.87
27,415
11.73M
US$ 20.410M
US$ 2.36
0.00 0.00
0
8.62M
US$ 20.340M
US$ 0.41
-0.04 -8.20
2.31M
48.05M
US$ 19.890M
US$ 1.09
-0.03 -2.68
390,505
18.00M
US$ 19.620M
US$ 1.06
0.01 0.95
20,368
18.06M
US$ 19.140M
US$ 10.00
0.36 3.73
13,972
1.88M
US$ 18.800M
US$ 3.26
-0.06 -1.66
14,693
5.55M
US$ 18.070M
US$ 13.60
0.00 0.00
0
1.32M
US$ 17.950M
US$ 1.14
0.00 0.00
88,129
15.51M
US$ 17.680M
US$ 34.50
-2.57 -6.93
264,785
505,798
US$ 17.450M
US$ 1.20
-0.05 -4.00
152,321
14.52M
US$ 17.420M
US$ 2.16
-0.32 -12.90
422,982
7.99M
US$ 17.260M
US$ 8.27
-0.73 -8.11
18,156
2.08M
US$ 17.200M
US$ 10.06
0.91 9.95
2.81M
1.67M
US$ 16.800M
US$ 1.90
-0.11 -5.47
40,650
8.82M
US$ 16.760M
US$ 1.42
0.01 0.71
27,644
11.70M
US$ 16.610M
US$ 4.20
-0.05 -1.18
20,737
3.94M
US$ 16.550M
US$ 4.43
-0.17 -3.65
4,176
3.65M
US$ 16.180M
US$ 0.26
0.002 0.77
10.39M
61.29M
US$ 16.120M
US$ 19.17
-0.19 -0.98
25,260
838,977
US$ 16.080M
US$ 7.44
0.44 6.29
67,679
2.15M
US$ 15.990M
US$ 1.58
0.06 3.95
330,953
10.09M
US$ 15.940M
US$ 2.53
-0.09 -3.44
175,151
6.16M
US$ 15.580M
C$ 0.06
0.00 0.00
0
258.84M
C$ 15.530M
US$ 1.20
-0.06 -4.76
153,432
12.93M
US$ 15.520M
US$ 1.19
0.01 0.85
203,545
12.94M
US$ 15.400M
C$ 0.09
0.00 0.00
175,010
181.05M
C$ 15.390M
US$ 3.62
-0.11 -2.95
21,915
4.24M
US$ 15.350M
C$ 0.20
0.00 0.00
0
76.57M
C$ 15.310M
US$ 3.03
-0.03 -0.82
296,031
4.93M
US$ 14.910M
US$ 0.26
-0.005 -1.87
931,382
56.64M
US$ 14.840M
US$ 1.38
-0.01 -0.72
33,026
10.61M
US$ 14.640M
US$ 0.05
0.00 0.00
0
265.05M
US$ 14.550M
US$ 0.93
-0.05 -5.46
93,096
15.49M
US$ 14.440M
C$ 0.03
0.00 0.00
1,000
570.65M
C$ 14.270M
US$ 3.20
-0.14 -4.19
20,871
4.35M
US$ 13.920M
US$ 1.01
-0.02 -1.94
43,497
13.78M
US$ 13.920M
US$ 1.23
-0.02 -1.60
289,126
10.76M
US$ 13.230M
US$ 0.66
0.03 4.44
2.27M
19.85M
US$ 13.060M
US$ 1.73
0.02 1.17
23,023
7.34M
US$ 12.700M
US$ 0.35
-0.06 -14.20
62.36M
35.74M
US$ 12.330M
US$ 1.74
0.01 0.58
8,519
6.95M
US$ 12.090M
US$ 3.91
-0.05 -1.26
30,106
3.07M
US$ 12.000M
US$ 0.22
0.00 0.00
0
55.66M
US$ 11.990M
US$ 0.36
-0.0074 -2.03
728,843
33.29M
US$ 11.920M
US$ 1.47
-0.04 -2.65
13,264
7.54M
US$ 11.080M
US$ 0.37
-0.0044 -1.17
364,765
29.71M
US$ 11.050M
US$ 0.85
0.03 4.12
237,225
12.85M
US$ 10.970M
C$ 0.12
0.005 4.35
43,256
91.02M
C$ 10.920M
US$ 8.20
-0.21 -2.50
11,686
1.26M
US$ 10.330M
US$ 1.43
-0.05 -3.38
35,112
7.17M
US$ 10.250M
US$ 2.06
-0.02 -0.96
7,153
4.81M
US$ 9.910M
C$ 0.07
0.01 18.18
15,084
151.90M
C$ 9.870M
C$ 0.09
-0.005 -5.26
27,770
108.62M
C$ 9.780M
US$ 5.00
4.44 793.56
17,666
1.92M
US$ 9.590M
US$ 1.20
-0.05 -4.00
48,445
7.85M
US$ 9.420M
US$ 0.20
0.00 0.00
0
47.31M
US$ 9.320M
US$ 1.12
-0.21 -15.79
28.17M
8.21M
US$ 9.200M
US$ 0.79
0.0005 0.06
45,467
11.64M
US$ 9.200M
US$ 1.02
-0.02 -1.92
37,290
8.88M
US$ 9.060M
US$ 1.20
0.04 3.45
11.17M
7.44M
US$ 8.930M
US$ 1.30
-1.80 -58.06
14.39M
6.83M
US$ 8.880M
US$ 2.72
0.00 0.00
0
3.18M
US$ 8.650M
US$ 8.56
0.00 0.00
0
973,291
US$ 8.330M
US$ 1.30
-0.02 -1.52
49,125
6.35M
US$ 8.260M
US$ 1.78
-0.17 -8.72
57,011
4.63M
US$ 8.240M
US$ 8.95
-0.06 -0.67
6,383
916,968
US$ 8.210M
US$ 0.36
0.00 0.00
0
23.14M
US$ 8.210M
US$ 0.76
-0.02 -3.09
1.13M
10.64M
US$ 8.040M
US$ 0.02
-0.0009 -3.61
319,800
332.96M
US$ 7.990M
US$ 2.55
-0.21 -7.61
37,848
3.13M
US$ 7.980M
C$ 0.15
0.00 0.00
5,500
52.95M
C$ 7.940M
US$ 0.14
0.00 0.00
0
55.37M
US$ 7.900M
US$ 1.21
-0.09 -6.92
113,414
6.45M
US$ 7.800M
US$ 2.05
-0.04 -1.91
64,096
3.80M
US$ 7.790M
US$ 3.98
-0.02 -0.50
16,212
1.91M
US$ 7.600M
US$ 0.31
-0.001 -0.32
160,105
23.99M
US$ 7.480M
US$ 7.19
4.03 127.53
425.08M
1.04M
US$ 7.480M
US$ 0.81
-0.06 -7.24
283,172
9.03M
US$ 7.320M
US$ 3.28
0.30 10.07
44,711
2.23M
US$ 7.310M
US$ 4.01
0.28 7.51
118,190
1.77M
US$ 7.100M
US$ 1.89
-0.04 -2.07
50,949
3.68M
US$ 6.960M
US$ 0.21
-0.01 -5.89
4.85M
33.74M
US$ 6.950M
US$ 3.31
-0.32 -8.82
43,330
2.09M
US$ 6.920M
US$ 0.08
0.0059 8.30
12,000
88.99M
US$ 6.850M
US$ 0.62
0.02 3.51
296
11.03M
US$ 6.840M
US$ 1.02
-0.09 -8.11
70,638
6.31M
US$ 6.440M
US$ 0.37
-0.02 -4.00
1.20M
17.07M
US$ 6.350M
US$ 4.61
0.00 0.00
0
1.33M
US$ 6.120M
US$ 0.46
-0.004 -0.87
80,146
13.32M
US$ 6.070M
US$ 2.84
0.00 0.00
0
2.12M
US$ 6.020M
US$ 0.20
0.00 0.00
0
30.12M
US$ 5.930M
US$ 1.53
-0.03 -1.92
29,023
3.81M
US$ 5.830M
US$ 2.22
-0.30 -11.75
1.16M
2.58M
US$ 5.710M
C$ 2.79
1.20 75.47
10,015
2.04M
C$ 5.690M
US$ 2.45
0.03 1.24
13,715
2.29M
US$ 5.610M
US$ 0.95
-0.01 -1.05
33,559
5.92M
US$ 5.600M
US$ 0.94
0.00 0.00
0
5.97M
US$ 5.580M
US$ 2.90
0.01 0.35
4,535
1.83M
US$ 5.310M
US$ 0.96
-0.02 -1.57
126,300
5.48M
US$ 5.260M
US$ 0.81
0.03 3.72
28,789
6.41M
US$ 5.180M
US$ 1.34
-0.01 -0.74
10,802
3.84M
US$ 5.150M
US$ 0.75
-0.0029 -0.39
1.18M
6.80M
US$ 5.080M
US$ 0.86
-0.02 -1.76
152,725
5.86M
US$ 5.010M
C$ 0.03
0.00 0.00
5.72M
166.23M
C$ 4.990M
US$ 1.28
0.10 8.47
1.13M
3.74M
US$ 4.790M
US$ 0.91
0.00 0.00
0
5.17M
US$ 4.700M
US$ 1.57
-0.08 -4.57
94,782
2.97M
US$ 4.650M
US$ 0.34
0.00 0.00
0
13.54M
US$ 4.560M
US$ 2.74
-0.11 -3.86
145,899
1.63M
US$ 4.470M
US$ 1.05
0.00 0.00
0
4.25M
US$ 4.460M
US$ 0.63
0.02 3.02
17,790
6.96M
US$ 4.390M
US$ 0.13
-0.01 -8.96
956.64M
33.18M
US$ 4.350M
US$ 2.02
0.05 2.54
8,430
2.15M
US$ 4.340M
C$ 0.01
0.00 0.00
64,000
432.32M
C$ 4.320M
US$ 0.99
-0.04 -3.88
53,696
4.23M
US$ 4.190M
US$ 0.50
0.00 0.00
0
8.21M
US$ 4.110M
US$ 2.57
-0.07 -2.65
21,061
1.56M
US$ 4.010M
US$ 1.19
-0.05 -4.03
98,826
3.33M
US$ 3.960M
US$ 0.53
-0.08 -13.11
123
7.24M
US$ 3.840M
US$ 0.03
0.00 0.00
0
118.11M
US$ 3.800M
US$ 0.35
0.01 2.94
178,000
10.74M
US$ 3.760M
US$ 6.51
-0.32 -4.69
4,695
574,580
US$ 3.740M
US$ 1.32
0.05 3.94
91,168
2.80M
US$ 3.700M
US$ 1.89
-0.06 -3.08
95,856
1.93M
US$ 3.650M
US$ 1.80
-0.03 -1.64
2.01M
2.02M
US$ 3.640M
US$ 0.85
0.01 1.55
21,163
4.17M
US$ 3.560M
US$ 2.00
0.05 2.56
4,841
1.75M
US$ 3.500M
US$ 5.82
0.10 1.75
12,292
596,978
US$ 3.470M
US$ 1.03
0.03 3.00
54,115
3.19M
US$ 3.290M
US$ 2.00
0.00 0.00
0
1.61M
US$ 3.220M
C$ 0.01
0.005 100.00
20,000
312.86M
C$ 3.130M
US$ 2.99
-0.06 -1.97
15,909
1.03M
US$ 3.080M
C$ 0.03
0.00 0.00
4,001
121.27M
C$ 3.030M
US$ 4.86
0.23 4.97
18,182
619,523
US$ 3.010M
C$ 0.13
0.00 0.00
1,560
21.15M
C$ 2.750M
C$ 0.08
0.00 0.00
8,000
34.26M
C$ 2.740M
US$ 0.56
0.00 0.00
0
4.52M
US$ 2.530M
US$ 0.02
0.00 0.00
0
124.38M
US$ 2.490M
US$ 0.77
-0.0038 -0.49
3,410
3.18M
US$ 2.430M
US$ 0.25
0.00 0.00
0
9.66M
US$ 2.390M
C$ 0.03
0.00 0.00
0
75.74M
C$ 2.270M
US$ 0.05
-0.0018 -3.41
116,245
41.85M
US$ 2.130M
US$ 0.39
0.00 0.00
0
5.23M
US$ 2.040M
US$ 0.02
0.0028 13.21
140,528
75.46M
US$ 1.810M
US$ 0.10
0.00 0.00
0
17.21M
US$ 1.800M
US$ 0.39
0.0005 0.13
39,225
4.34M
US$ 1.710M
US$ 0.05
0.003 6.98
21,044
33.71M
US$ 1.550M
C$ 0.005
0.00 0.00
0
283.28M
C$ 1.420M
US$ 2.48
-0.33 -11.74
745,341
559,444
US$ 1.390M
US$ 0.09
0.00 0.00
0
16.39M
US$ 1.390M
US$ 0.28
-0.06 -16.62
10,000
4.62M
US$ 1.280M
US$ 0.002
0.0005 33.33
60,000
635.87M
US$ 1.270M
C$ 0.09
0.00 0.00
0
13.86M
C$ 1.250M
US$ 0.30
0.00 0.00
0
3.78M
US$ 1.130M
US$ 0.13
0.0005 0.37
19,309
8.10M
US$ 1.090M
US$ 1.82
-0.04 -2.15
599,037
578,625
US$ 1.050M
US$ 0.20
0.00 0.00
0
4.44M
US$ 894K
US$ 0.07
0.00 0.00
600
11.62M
US$ 813K
US$ 0.11
0.00 0.00
0
6.58M
US$ 705K
US$ 0.02
0.00 0.00
0
29.49M
US$ 678K
US$ 0.07
0.003 4.29
365
8.31M
US$ 607K
US$ 0.25
0.00 0.00
0
1.63M
US$ 413K
US$ 0.21
0.00 0.00
0
1.55M
US$ 326K
US$ 0.008
0.00 0.00
0
39.74M
US$ 318K
US$ 0.07
0.00 0.00
0
4.44M
US$ 289K
US$ 0.004
0.00 0.00
0
61.76M
US$ 247K
US$ 0.001
0.00 0.00
0
232.37M
US$ 232K
US$ 0.37
0.00 0.00
0
581,000
US$ 215K
US$ 0.16
0.00 0.00
0
1.33M
US$ 206K
US$ 0.02
0.00 0.00
0
4.85M
US$ 97K
US$ 0.005
0.00 0.00
0
5.23M
US$ 26K
US$ 0.02
0.00 0.00
0
1.24M
US$ 26K
US$ 0.01
0.00 0.00
0
863,788
US$ 10K
US$ 0.07
0.00 0.00
0
-
US$ -
US$ 0.001
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
4.87M
US$ -
US$ 1.06
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -
US$ 3.01
0.00 0.00
0
-
US$ -
US$ 0.001
0.00 0.00
0
-
US$ -
US$ 32.95
0.00 0.00
0
-
US$ -
US$ 1.20
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
1.39M
US$ -
US$ 0.00
0.00 0.00
0
125.63M
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -
US$ 0.001
0.00 0.00
0
-
US$ -
US$ 0.02
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
5.12B
US$ -
US$ 0.02
0.00 0.00
0
-
US$ -
US$ 0.001
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
261.79M
US$ -
US$ 1.95
-0.02 -1.02
157,789
-
US$ -
C$ 3.35
0.00 0.00
0
-
C$ -
US$ 1.58
-0.04 -2.47
129,028
-
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -

Latest Biotechnology Stock News


Clene to Provide CNM-Au8® ALS Program Update

Webcast set for 8:30 a.m. ET on December 3rd SALT LAKE CITY, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced it plans provide an update on its CNM-Au8... Read more


ADC Therapeutics to Provide Update on LOTIS-7 Clinical Trial

Company to host corporate webcast to share updated data on December 3, 2025 LAUSANNE, Switzerland, Dec. 2, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it will host a conference call and live webcast on Wednesday, December 3, 2025, at 8:00 a.m. EST to provide an update on the LOTIS-7 Phase 1b open-label clinical trial evaluating the safety and... Read more


Jazz Pharmaceuticals to Present Pivotal Phase 3 Results of Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma at the 2026...

Late-breaking HERIZON-GEA-01 presentation highlights the expanding clinical profile of Ziihera across HER2-driven gastrointestinal cancers Jazz to host investor webcast on Friday, January 9, 2026, to review data DUBLIN, Dec. 2, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced two abstracts featuring key data for Ziihera® (zanidatamab-hrii) have been accepted for presentation at the American Society of Clinical Oncology... Read more


FibroGen to Present at the Oppenheimer Movers in Rare Disease Summit

SAN FRANCISCO, Dec. 02, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the Company will be attending and presenting at the Oppenheimer Movers in Rare Disease Summit being held on December 11, 2025, in New York, NY. Thane Wettig, Chief Executive Officer of FibroGen, will participate in a panel titled Elevator Pitches from Rare Disease Companies with Key Near-Term, Potentially Stock-Moving Catalysts on Thursday, December 11 at 12:15... Read more


Black Diamond Therapeutics to Host Webcast Presentation Highlighting Silevertinib Phase 2 Clinical Trial Results and Program Update

Webcast to be held Wednesday, December 3, at 8:00am ET CAMBRIDGE, Mass., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, will host a webcast to present results from its Phase 2 clinical trial of silevertinib and provide a program update on Wednesday, December 3, 2025, at 8:00am ET. Webcast information The... Read more


PharmaTher Closes Sale of Ketamine ANDA, Sharpening Focus on Long-Acting Injectable Ketamine Franchise

Toronto, Ontario--(Newsfile Corp. - December 2, 2025) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty life sciences company focused on unlocking the therapeutic potential of ketamine for neuropsychiatric disorders, today announced it has closed the previously announced sale of its Abbreviated New Drug Application (ANDA #217858) for Ketamine Hydrochloride Injection USP to a leading sterile-injectables pharmaceutical company. At... Read more


Creative Medical Technology Announces World Health Organization Approval of “olastrocel” as INN for Lead Allogeneic Cell Therapy CELZ-201

Global assignment of this unique name enhances international clarity, strengthens regulatory positioning, and supports olastrocel’s advancement across large unmet-need global markets PHOENIX, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical” or the “Company”), a clinical-stage biotechnology company developing next-generation regenerative and immune cell therapies, today announced that the World... Read more


Longeveron Granted Canadian Patent for Method of Using Stem Cells to Treat Non-Ischemic Dilated Cardiomyopathy and Aging-related Frailty in Patients with Inflammaging

The patent relates to methods of administering therapeutically effective amounts of isolated allogeneic mesenchymal stem cells (MSCs) to patients with aging-related frailty with inflammaging and also to treat patients with non-ischemic dilated cardiomyopathy Non-ischemic dilated cardiomyopathy is a progressive disorder with no current cure, often leading to heart transplantation No approved treatments for aging-related frailty, a syndrome affecting older individuals... Read more


Hemostemix to Attend DFCon San Antonio and Closed its Private Placement

Calgary, Alberta--(Newsfile Corp. - December 2, 2025) - Hemostemix (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is proud to announce its participation in DFCon 2025, hosted by the American Limb Preservation Society in San Antonio, Texas - the global epicentre for innovation in diabetic foot care, vascular medicine, and limb preservation. With more than 500 delegates expected, DFCon gathers the widest spectrum of professionals shaping the future of diabetic limb salvage: podiatrists,... Read more


IGC Pharma Announces Publication of Landmark Caregiver Book on Alzheimer's Disease

New Caregiver Resource Showcases Expert Contributions and Reinforces IGC Pharma's Leadership in Alzheimer's Innovation POTOMAC, MD / ACCESS Newswire / December 2, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company leveraging Artificial Intelligence (AI) to develop innovative treatments for Alzheimer's disease, today announced the publication of "Caring for a Loved One with Alzheimer's Disease: First Hand Ex... Read more


Jaguar Health Makes Submission to EMA Regarding EU Approval Pathway for Canalevia for General Diarrhea in Dogs Based on Data from Completed Study

Jaguar's requesting advice from EMA on EU approval pathway for general diarrhea of FDA conditionally approved Canalevia® A novel non-antibiotic approach to diarrhea treatment is important because there are no FDA-approved drugs to treat general diarrhea in dogs, the second most common reason for visits to veterinary emergency hospitals SAN FRANCISCO, CA / ACCESS Newswire / December 2, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar), today announced that its Italian... Read more


Alpha Tau Medical Receives FDA Approval to Initiate a Trial for Patients with Locally Recurrent Prostate Cancer

FDA approval marks Alpha Tau’s fifth simultaneous active U.S. IDE as the Company expands Alpha DaRT’s reach into recurrent prostate cancer  JERUSALEM, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that the FDA has approved an Investigational Device Exemption (IDE) application to initiate a pilot study for the treatment of patients with... Read more


PDS Biotechnology Announces Scheduling of Type C Meeting with U.S. Food and Drug Administration (“FDA”)

Company to Discuss Proposed Amendment to Phase 3 VERSATILE-003 Trial Enabling Potential Accelerated Approval Pathway PRINCETON, N.J., Dec. 02, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that its request for a Type C Meeting with the FDA has been accepted by the agency, and the... Read more


NRx Pharmaceuticals Announces US Food and Drug Administration (FDA) Receipt of ANDA for KETAFREE™, a Preservative-Free IV Ketamine

FDA has determined that NRx’s Abbreviated New Drug Application (ANDA) is “substantially complete” and received for review. Assigned GDUFA goal date is July 29, 2026. NRx has applied to FDA for use of KETAFREE™ as a proprietary product name, which is subject to review. KETAFREE™ is the first preservative-free ketamine formulation that does not include potentially toxic preservatives used in current multidose presentations of ketamine. Current worldwide generic... Read more


Fulcrum Therapeutics to Host Investor Event to Review New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease on December 7, 2025

CAMBRIDGE, Mass., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, will host an investor event on Sunday, December 7, 2025 at 7:00 a.m. ET to review new clinical data from the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD). These data will also be presented at the 67th American... Read more


Savara and PARI Granted a European Patent Covering the Drug-Device Combination of MOLBREEVI* Delivered Via the Proprietary eFlow® Nebulizer System

LANGHORNE, Pa. / Dec 02, 2025 / Business Wire / Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the European Patent Office (EPO) has issued patent No. 4 496 611 titled, “Drug-Device Combination Comprising a Liquid Solution and a Nebulizer for Aerosolization of the Liquid Solution.” The patent is jointly held by Savara and PARI and covers the combination of Savara’s investigational therapy,... Read more


Ensysce Biosciences Announces Broader Patent Protection for Groundbreaking MPAR(R) Overdose Protection Technology

New U.S. Patent Extends Protection Through 2042  Patent Allowance Secures Highest Level of Intellectual Property Protection for MPAR®  SAN DIEGO, CA / ACCESS Newswire / December 2, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company pioneering next-generation pain and central nervous system therapeutics designed to minimize abuse and overdose risk, today announced that the U.S. Patent and... Read more


Harmony Biosciences to Present New Open-Label Extension Data from Phase 3 ARGUS Trial at the 2025 American Epilepsy Society Annual Meeting

PLYMOUTH MEETING, Pa. / Dec 02, 2025 / Business Wire / Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that it will highlight new open-label extension data from the company’s investigation of EPX-100 (clemizole hydrochloride) in the ongoing Phase 3 ARGUS trial for the treatment of Dravet syndrome at the 2025 American Epilepsy Society (AES) Annual Meeting being held December 5 – December 9, 2025, in Atlanta, GA. The ARGUS trial is currently enrolling,... Read more


Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber Neuropathy

RICHMOND, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to ST-503, an investigational epigenetic regulator for the treatment of intractable pain due to small fiber neuropathy (SFN), a type of chronic neuropathic pain. Fast Track Designation aims to facilitate the development and expedite the review of new... Read more


Insilico Medicine and Atossa Therapeutics Publish AI-Driven Study in Nature Scientific Reports Identifying (Z)-Endoxifen as a Potential Therapeutic Candidate for Glioblastoma

CAMBRIDGE, Mass., Dec. 2, 2025 /PRNewswire/ -- Insilico Medicine ("Insilico"), a global leader in AI-powered drug discovery, and Atossa Therapeutics ("Atossa") (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel treatments for breast cancer and other serious conditions, announce the publication of a joint study evaluating the potential of (Z)-endoxifen for glioblastoma multiforme (GBM). The peer-reviewed article, now published in Nature's Scientific... Read more


Chemomab Therapeutics Announces Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis Published in the American Journal of Gastroenterology

New Peer-Reviewed Publication Highlights Phase 2 SPRING Trial Data Supporting the Disease Modifying Potential of Nebokitug in PSC and Supports Advancement to a Phase 3 Registration Trial TEL AVIV, Israel, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that the results of its Phase 2... Read more


Oncotelic Therapeutics and Sapu Nano Unveils Broad-Applicability Deciparticle™ Nanomedicine Platform Capable of Formulating Multiple Hydrophobic Peptide, Macrolide, and Polyketide Drugs

AGOURA HILLS, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC) 45% owned Joint Venture, Sapu Nano, a clinical-stage nanomedicine company, today announced new data demonstrating that its proprietary Deciparticle™ platform enables broad and consistent formulation of structurally diverse hydrophobic therapeutics—including macrolide mTOR inhibitors, cyclic peptides, linear peptides, ascomycin macrolactams, and polyketides—while... Read more


First U.S. Commercial Sale of KOMZIFTI™ Triggers $135 Million Milestone Payment to Kura Oncology Under Collaboration and License Agreement with Kyowa Kirin

SAN DIEGO, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA, “Kura”), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the first U.S. commercial sale of KOMZIFTI™ (ziftomenib) has been completed. Under Kura’s collaboration and license agreement with Kyowa Kirin Co. Ltd. and Kyowa Kirin, Inc. (collectively, “Kyowa Kirin”), this milestone triggers a $135 million... Read more


Silexion Therapeutics Receives Positive Feedback from German Health Authority on Design of Phase 2/3 Clinical Trial in Pancreatic Cancer

Positive feedback reinforces Silexion’s trajectory toward its planned Phase 2/3 trial initiation in Q2 2026 Company plans to complete regulatory submissions to the Israeli Ministry of Health by the end of Q4 2025 and in Germany during Q1 2026 GRAND CAYMAN, Cayman Islands, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company developing RNA interference (RNAi) therapies... Read more


Acumen Pharmaceuticals Highlights Enhanced Brain Delivery™ Technology for Oligomer-Selective Antibodies and Recruitment Strategies for Phase 2 ALTITUDE-AD Clinical Trial at 18th Annual Clinical Trials...

NEWTON, Mass., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), today announced new research at the 18th Annual Clinical Trials on Alzheimer’s Disease (CTAD) conference, taking place December 1-4, 2025, in San Diego and online. Results from a collaborative study... Read more


Immutep to Present New Data from AIPAC-003 Phase II at the 2025 San Antonio Breast Cancer Symposium

Immunotherapy-chemotherapy combination of eftilagimod alfa (efti) and paclitaxel led to strong objective response rates and immune activation in heavily pretreated metastatic breast cancer patients AIPAC-003 has resulted in successful completion of FDA’s Project Optimus requirements and selection of 30 mg as efti’s optimal biological dose SYDNEY, AUSTRALIA, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”),... Read more


Clearmind Medicine Advances CMND-100 to Dosing Phase at Hadassah Medical Center in Ongoing Phase I/IIa Clinical Trial for Alcohol Use Disorder

Vancouver, Canada, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced another key milestone in its Phase I/IIa clinical trial for the treatment of Alcohol Use Disorder (AUD): the first participant has been enrolled and dosed with... Read more


Polyrizon Announces Successful Completion of Key Manufacturing Upscaling Milestone for Its Nasal Spray Platform

Ra’anana, Israel, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a biotechnology company developing intranasal products based on its proprietary Capture & Contain (C&C) platform, today announced the successful completion of a major manufacturing upscaling milestone for its proprietary nasal-spray product platform. This achievement marks a critical step toward supporting upcoming clinical and regulatory... Read more


Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran in Severe Hypertriglyceridemia

PASADENA, Calif. / Dec 02, 2025 / Business Wire / Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the United States Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to investigational plozasiran as an adjunct to diet to reduce triglyceride (TG) levels in adults with severe hypertriglyceridemia (SHTG) (TG levels greater than or equal to 500 mg/dL). There are currently limited and inadequate treatment options for the millions... Read more


BriaCell Therapeutics to Present Phase 2 Survival & Phase 3 Clinical Data at SABCS® 2025

Three poster presentations at the San Antonio Breast Cancer Symposium (SABCS), now available and to be presented on December 10, 2025, highlight robust survival and clinical benefit data in Phase 2, plus positive key biomarker data from the pivotal Phase 3  The pivotal Phase 3 study of Bria-IMT+CPI in advanced metastatic breast cancer is ongoing with an interim analysis expected in 1H2026 PHILADELPHIA and VANCOUVER, British Columbia, Dec. 02, 2025 (GLOBE NEWSWIRE)... Read more


Ventyx Biosciences Provides Clinical and Corporate Updates

Strengthening our Advisory Board with addition of Mark McKenna as Strategic Advisor and Peter Libby, MD as a Clinical Advisor Expanding the Phase 2 recurrent pericarditis study into Canada, EU and the UK to evaluate QD dose ranging in preparation for the global Phase 3 development plan Interim analysis for the ongoing Phase 2 recurrent pericarditis study to now be presented as part of Ventyx’s R&D Day planned for Q1 2026 SAN DIEGO, Dec. 02, 2025 (GLOBE NEWSWIRE)... Read more


Fennec Pharmaceuticals Announces Positive Topline Results From Investigator-Initiated Clinical Study of PEDMARK® in Japan to Reduce Cisplatin-Induced Hearing Loss

Study, Which Enrolled 27 Patients, Met Primary Endpoint with a Significant Reduction in Hearing Loss in 3-18 Year Old Patients who Received PEDMARK® when Compared with Historically Reported Rates of Hearing Loss in Patients Receiving Cisplatin Alone (16-24% versus 56-63%, Respectively)  PEDMARK® Showed No Interference with Cisplatin Antitumor Activity as Evidenced by an Approximate 95% Clinical Response Rate  The Company Plans to Pursue Registration and... Read more


Ionis Pharmaceuticals receives U.S. FDA Breakthrough Therapy designation for zilganersen for Alexander disease (AxD)

First and only investigational medicine for this rare, often fatal neurological condition  On track to submit new drug application (NDA) in Q1 2026  CARLSBAD, Calif. / Dec 02, 2025 / Business Wire / Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to zilganersen for the treatment of Alexander disease (AxD), a rare, progressive and often fatal neurological... Read more


CervoMed Presents New Plasma Biomarker Data That Indicates Neflamapimod Broadly Improves Neuroinflammation and Neurodegeneration in Dementia with Lewy Bodies (DLB)

1st of two presentations with results from Phase 2b study of neflamapimod at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference Data demonstrates neflamapimod treatment led to significant reductions in plasma glial fibrillary acidic protein (GFAP), a key marker of neuroinflammation-associated neurodegeneration, and increased beta amyloid (A) 42/40 ratio in DLB Correlation of the effects of neflamapimod on plasma GFAP with positive treatment response,... Read more


Fractyl Health Reports Positive 6-Month REVEAL-1 Open-Label Results Showing Sustained Post-GLP-1 Weight Maintenance After a Single Revita® Procedure

Participants who lost 24% total body weight (>50 lbs.) on GLP-1 drugs maintained stable weight 6 months after GLP-1 discontinuation and single Revita treatment 1.5% mean weight change observed with Revita (n=17); published third-party studies after GLP-1 withdrawal alone have shown ~10% weight regain at similar time points Upcoming randomized 6-month REMAIN-1 Midpoint Cohort data expected in January 2026; topline 6-month Pivotal Cohort data and potential PMA filing... Read more


Jasper Therapeutics Reports Positive Preliminary Data from ETESIAN Study of Briquilimab in Asthma and Findings from BEACON Study Internal Investigation

Reductions in airway hyperresponsiveness and suppressed eosinophilic response at both 6 weeks and 12 weeks observed after a single 180mg dose of Briquilimab in the ETESIAN Study Preliminary data from ETESIAN study supports further development of briquilimab in asthma Jasper also announces completion of internal BEACON study investigation noting no deviations or issues with drug product utilized Jasper to host conference call and webinar today at 8:00 a.m. ET REDWOOD... Read more


Tiziana Life Sciences Plans to Spinout IL-6 Asset into Separate Listed Company

BOSTON, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies, today announced that it intends to develop its fully human anti-IL-6 receptor (IL-6R) monoclonal antibody, TZLS-501, and related assets (together “TZLS-501”) via a spinout into a separate publicly traded company, to enhance the strategic focus of each company and to... Read more


Pasithea Therapeutics Announces Closing of $60 Million Public Offering of Common Stock

Extends cash runway through at least the first half of 2028 Led by healthcare-dedicated investors, including Vivo Capital, Janus Henderson Investors, Coastlands Capital, Columbia Threadneedle Investments, Adage Capital Partners and Squadron Capital Management MIAMI, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (“Pasithea” or the “Company”) (Nasdaq: KTTA; KTTAW), a clinical-stage biotechnology company developing PAS-004, a next-generation... Read more


Zevra Therapeutics Appoints Alicia Secor to Board of Directors; Announces Retirement of Wendy Dixon, PhD

CELEBRATION, Fla., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced the appointment of Alicia Secor to the Company’s Board of Directors (Board). The Company also announced the retirement of director Wendy Dixon, PhD, effective today. "We are pleased to welcome Alicia to our Board at this important juncture,... Read more


Palisade Bio Strengthens Clinical Leadership Team with Appointment of James Izanec, MD, AGAF as Vice President, Clinical Development

Veteran gastroenterologist and clinical development leader with deep expertise driving global Phase 2/3 programs across immunology, neurology, and gastrointestinal disease Carlsbad, CA, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company advancing next-generation, once daily, oral PDE4 inhibitor prodrugs for patients with inflammatory and fibrotic diseases, today... Read more


Scinai Immunotherapeutics Reports Nine-Month 2025 Results as CDMO Growth Continues and NanoAbs Pipeline Advances

JERUSALEM, Dec. 2, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai", or the "Company"), a biopharmaceutical company developing innovative inflammation and immunology (I&I) therapeutics and operating a growing boutique CDMO business unit, today reported its financial results and corporate highlights for the nine months ended September 30, 2025. First Nine Months 2025 Financial Summary Revenues for the nine months ended September 30, 2025... Read more


COSCIENS Biopharma Announces Exclusive Distribution Agreement with Wuzhou Drug International for Macrilen® in Hainan-Guangdong-Hong Kong-Macao Greater Bay Area and Singapore

TORONTO, ONTARIO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (FINRA: CSCIF) (“COSCIENS” or the “Company”), a life sciences company focused on pharmaceutical therapies, diagnostic products, and natural ingredients solutions, today announced that its wholly-owned subsidiary, Aeterna Zentaris GmbH, has entered into an exclusive distribution agreement with Wuzhou Drug International Trading Limited (“Wuzhou”) for the commercialization... Read more


Jasper Therapeutics to Host an Investor Webinar on December 2nd to Present Preliminary Data from ETESIAN Study in Asthma and Findings from BEACON Study Investigation

Webinar to be held Tuesday, December 2nd, at 8:00 am ET REDWOOD CITY, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper or the Company), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced that the Company will... Read more


Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients on Wednesday, December 3, 2025

NEW YORK, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that it will host a conference call and live webcast at 8:30 am ET on Wednesday, December 3, 2025, to review new data from an interim analysis of the ongoing Phase 2 open-label ADVANCED-2 trial of TARA-002 in BCG-Naïve patients with non-muscle invasive bladder cancer... Read more


Biomea Fusion Announces Oral Presentation of Icovamenib at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)

SAN CARLOS, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that it has been selected for an oral presentation of its long-term icovamenib follow up data at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) taking place in Los Angeles, California on December 3-6, 2025. The Congress... Read more


Janux Therapeutics Announces Encouraging Efficacy and Safety Profile from Ongoing Phase 1 Clinical Trial for JANX007 in mCRPC

Phase 1 data demonstrates durable responses and rPFS coupled with a manageable safety profile rPFS of 7.9-8.9 months in heavily pre-treated mCRPC patients Preliminary results are encouraging with deep PSA reductions and a promising CRS profile in taxane-naïve Phase 1b expansion study Initial results support a patient-friendly Q2W dosing schedule Janux to host virtual investor event today at 4:30 PM Eastern Time SAN DIEGO / Dec 01, 2025 / Business Wire / Janux... Read more


Caribou Biosciences to Host In-Person and Virtual KOL Event at ASH 2025

KOL panel to discuss how vispa-cel, an anti-CD19 allogeneic CAR-T cell therapy, can broaden access for patients with second-line large B cell lymphoma including through use in the community setting BERKELEY, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that it will host an expert physician panel discussion during an ancillary event at the... Read more


Citius Oncology Announces U.S. Commercial Launch of LYMPHIR™, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL)

LYMPHIR now available nationwide CRANFORD, N.J., Dec. 1, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today announced the commercial launch of LYMPHIR™ (denileukin diftitox-cxdl). LYMPHIR is a novel IL-2 receptor-directed fusion protein approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed... Read more


Longeveron New MRI Biomarker Data Linking Neuroinflammation to Clinical Outcomes in Patients with Mild Alzheimer’s Disease Presented at the Clinical Trials on Alzheimer’s Disease Conference (CTAD

Results obtained in the Phase 2 placebo-controlled CLEAR-MIND clinical trial showed that treatment with stem cell therapy laromestrocel was associated with a reduction in MRI measured neuroinflammation compared to placebo across multiple key brain regions, including key Alzheimer’s disease-associated regions, most notably in the hippocampus Reduction in hippocampal neuroinflammation, measured using MRI assessed free water, correlated strongly with preservation of... Read more


Clearmind Medicine Charges Forward in Alcoholism Treatment: Positive Cohort Data, Full DSMB Approval, and New Elite Site Joins the Clinical Trial

Vancouver, Canada, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, recently announced three transformative milestones in its FDA-approved Phase I/IIa clinical trial for CMND-100—the Company's proprietary, non-hallucinogenic, MEAI-based oral... Read more